CAR-T cell therapy provides early and deep response in multiple myeloma patients

Initial data from the phase II study CARTITUDE-2 show that patients with refractory multiple myeloma received an early and deep response to treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta cell).